Advertisement

Adjuvant chemotherapy for high-grade appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy

Published:September 01, 2022DOI:https://doi.org/10.1016/j.ejso.2022.08.022

      Abstract

      Introduction

      There are no available data on the efficacy of adjuvant chemotherapy (ACT) in stage IVA/B high-grade mucinous appendiceal cancer treated with CRS/HIPEC. We evaluated the association between ACT and survival in this cohort.

      Materials and methods

      A single-institution retrospective cohort study using a prospective database was conducted. Stage IVA/B high-grade mucinous appendiceal cancer patients who underwent CRS/HIPEC with CC-0/1 were included. Survival was compared between ACT and no chemotherapy (NoCT) patients. Subgroup analysis was performed with adjustment for confounding variables.

      Results

      We identified 180 patients: 77 ACT and 103 NoCT. ACT regimens included 5-FU/capecitabine (13%), oxaliplatin-based (63%), and irinotecan-based (21%), combined with bevacizumab in 27% of cases. Median number of cycles was 9 (IQR: 6–12). Median overall survival (OS) did not significantly differ between ACT and NoCT (53 vs 75 months, p = 0.566). Multivariable Cox regression showed no OS benefit for ACT vs NoCT in patients with neoadjuvant chemotherapy (HR 1.14; 95%CI: 0.38–3.39) or without it (HR 1.33; 95%CI: 0.69–2.57), with signet ring cell (HR 0.89; 95%CI: 0.38–2.06) or other histologies (HR 1.11; 95%CI: 0.50–2.46), positive lymph nodes (HR 1.60; 95%CI: 0.74–3.49), or peritoneal cancer index ≥20 (HR 1.08; 95%CI: 0.55–2.11) after adjusting for other factors.

      Conclusions

      In our cohort, colon-type ACT was not associated with better OS in stage IVA/B mucinous appendiceal cancer after CRS/HIPEC, even after adjusting for confounders. This may be due to different tumor biology than colon cancer or small sample size. Prospective collaborative studies are needed.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Surgical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kusamura S.
        • Barretta F.
        • Yonemura Y.
        • et al.
        The role of hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei after cytoreductive surgery.
        JAMA Surg. 2021; 156e206363
        • Kolla B.C.
        • Petersen A.
        • Chengappa M.
        • et al.
        Impact of adjuvant chemotherapy on outcomes in appendiceal cancer.
        Cancer Med. 2020; 9: 3400-3406
        • Cummins K.A.
        • Russell G.B.
        • Votanopoulos K.I.
        • Shen P.
        • Stewart J.H.
        • Levine E.A.
        Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
        J Gastrointest Oncol. 2016; 7: 3-9
        • Byrne R.M.
        • Gilbert E.W.
        • Dewey E.N.
        • et al.
        Who undergoes cytoreductive surgery and perioperative intraperitoneal chemotherapy for appendiceal cancer? An analysis of the national cancer database.
        J Surg Res. 2019; 238: 198-206
        • Asare E.A.
        • Compton C.C.
        • Hanna N.N.
        • et al.
        The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: analysis of the National Cancer Data Base.
        Cancer. 2016; 122: 213-221
        • Sugarbaker P.H.
        New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?.
        Lancet Oncol. 2006; 7: 69-76
        • Carr N.J.
        • Bibeau F.
        • Bradley R.F.
        • et al.
        The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei.
        Histopathology. 2017; 71: 847-858
        • Jacquet P.
        • Sugarbaker P.H.
        Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis.
        Cancer Treat Res. 1996; 82: 359-374
        • Nikiforchin A.
        • Gushchin V.
        • King M.C.
        • et al.
        Surgical and oncological outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a nonacademic center: 25-year experience.
        J Surg Oncol. 2021; 123: 1030-1044
        • Dindo D.
        • Demartines N.
        • Clavien P.A.
        Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.
        Ann Surg. 2004; 240: 205-213
        • Shankar S.
        • Ledakis P.
        • El Halabi H.
        • Gushchin V.
        • Sardi A.
        Neoplasms of the appendix: current treatment guidelines.
        Hematol Oncol Clin N Am. 2012; 26: 1261-1290
        • Chen J.C.
        • Beal E.W.
        • Hays J.
        • Pawlik T.M.
        • Abdel-Misih S.
        • Cloyd J.M.
        Outcomes of neoadjuvant chemotherapy before CRS-HIPEC for patients with appendiceal cancer.
        J Surg Oncol. 2020; 122: 388-398
        • Bekhor E.
        • Carr J.
        • Hofstedt M.
        • et al.
        The safety of iterative cytoreductive surgery and HIPEC for peritoneal carcinomatosis: a high volume center prospectively maintained database analysis.
        Ann Surg Oncol. 2020; 27: 1448-1455
        • Lopez-Ramirez F.
        • Gushchin V.
        • Sittig M.
        • et al.
        Iterative cytoreduction and hyperthermic intraperitoneal chemotherapy for recurrent mucinous adenocarcinoma of the appendix.
        Ann Surg Oncol. 2022; 29: 3390-3401
        • Rovers K.P.
        • Bakkers C.
        • van Erning F.N.
        • et al.
        Adjuvant systemic chemotherapy vs active surveillance following up-front resection of isolated synchronous colorectal peritoneal metastases.
        JAMA Oncol. 2020; 6e202701
        • Maillet M.
        • Glehen O.
        • Lambert J.
        • et al.
        Early postoperative chemotherapy after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for isolated peritoneal carcinomatosis of colon cancer: a multicenter study.
        Ann Surg Oncol. 2016; 23: 863-869
        • Tokunaga R.
        • Xiu J.
        • Johnston C.
        • et al.
        Molecular profiling of appendiceal adenocarcinoma and comparison with right-sided and left-sided colorectal cancer.
        Clin Cancer Res. 2019; 25: 3096-3103
        • Levine E.A.
        • Blazer 3rd, D.G.
        • Kim M.K.
        • et al.
        Gene expression profiling of peritoneal metastases from appendiceal and colon cancer demonstrates unique biologic signatures and predicts patient outcomes.
        J Am Coll Surg. 2012; 214 (; discussion 606-597): 599-606
        • André T.
        • de Gramont A.
        • Vernerey D.
        • et al.
        Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study.
        J Clin Oncol. 2015; 33: 4176-4187
        • Kuebler J.P.
        • Wieand H.S.
        • O'Connell M.J.
        • et al.
        Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
        J Clin Oncol. 2007; 25: 2198-2204
        • Haller D.G.
        • Tabernero J.
        • Maroun J.
        • et al.
        Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
        J Clin Oncol. 2011; 29: 1465-1471
        • Halabi H.E.
        • Gushchin V.
        • Francis J.
        • et al.
        Prognostic significance of lymph node metastases in patients with high-grade appendiceal cancer.
        Ann Surg Oncol. 2012; 19: 122-125
        • Mercier F.
        • Dagbert F.
        • Pocard M.
        • et al.
        Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
        BJS Open. 2019; 3: 195-202
        • van Gestel Y.R.
        • de Hingh I.H.
        • van Herk-Sukel M.P.
        • et al.
        Patterns of metachronous metastases after curative treatment of colorectal cancer.
        Cancer Epidemiol. 2014; 38: 448-454
        • van Oudheusden T.R.
        • Nienhuijs S.W.
        • Luyer M.D.
        • et al.
        Incidence and treatment of recurrent disease after cytoreductive surgery and intraperitoneal chemotherapy for peritoneally metastasized colorectal cancer: a systematic review.
        Eur J Surg Oncol. 2015; 41: 1269-1277
        • Sugarbaker P.H.
        • Van der Speeten K.
        • Stuart O.A.
        Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer.
        World J Gastrointest Oncol. 2010; 2: 19-30
        • Kitai T.
        • Yamanaka K.
        • Sugimoto N.
        • Inamoto O.
        Surgical management for peritoneal carcinomatosis of appendiceal origin with a high-tumor burden.
        Surg Today. 2020; 50: 171-177
        • Yonemura Y.
        • Canbay E.
        • Wakama S.
        • et al.
        Analysis of treatment failure after complete cytoreductive surgery for peritoneal metastasis from appendiceal mucinous neoplasm at a Japanese high volume center for peritoneal surface malignancy.
        Gan To Kagaku Ryoho. 2019; 46: 251-258
        • Turaga K.K.
        • Pappas S.G.
        • Gamblin T.C.
        Importance of histologic subtype in the staging of appendiceal tumors.
        Ann Surg Oncol. 2012; 19: 1379-1385
        • Baratti D.
        • Kusamura S.
        • Milione M.
        • Bruno F.
        • Guaglio M.
        • Deraco M.
        Validation of the recent PSOGI pathological classification of pseudomyxoma peritonei in a single-center series of 265 patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
        Ann Surg Oncol. 2018; 25: 404-413
        • Munoz-Zuluaga C.
        • Sardi A.
        • King M.C.
        • et al.
        Outcomes in peritoneal dissemination from signet ring cell carcinoma of the appendix treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
        Ann Surg Oncol. 2019; 26: 473-481
        • Levinsky N.C.
        • Morris M.C.
        • Wima K.
        • et al.
        Should we Be doing cytoreductive surgery with HIPEC for signet ring cell appendiceal adenocarcinoma? A study from the US HIPEC collaborative.
        J Gastrointest Surg. 2020; 24: 155-164
        • Lieu C.H.
        • Lambert L.A.
        • Wolff R.A.
        • et al.
        Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix.
        Ann Oncol. 2012; 23: 652-658
        • Chua T.C.
        • Pelz J.O.
        • Kerscher A.
        • Morris D.L.
        • Esquivel J.
        Critical analysis of 33 patients with peritoneal carcinomatosis secondary to colorectal and appendiceal signet ring cell carcinoma.
        Ann Surg Oncol. 2009; 16: 2765-2770
        • Sinukumar S.
        • Mehta S.
        • As R.
        • et al.
        Analysis of clinical outcomes of pseudomyxoma peritonei from appendicular origin following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy-A retrospective study from INDEPSO.
        Indian J Surg Oncol. 2019; 10: 65-70
        • Votanopoulos K.I.
        • Russell G.
        • Randle R.W.
        • Shen P.
        • Stewart J.H.
        • Levine E.A.
        Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases.
        Ann Surg Oncol. 2015; 22: 1274-1279
        • Blackham A.U.
        • Swett K.
        • Eng C.
        • et al.
        Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
        J Surg Oncol. 2014; 109: 740-745
        • Munoz-Zuluaga C.A.
        • King M.C.
        • Ledakis P.
        • et al.
        Systemic chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade mucinous carcinoma peritonei of appendiceal origin.
        Eur J Surg Oncol. 2019; 45: 1598-1606
        • Sugarbaker P.H.
        • Bijelic L.
        • Chang D.
        • Yoo D.
        Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin.
        J Surg Oncol. 2010; 102: 576-581
        • Shapiro J.F.
        • Chase J.L.
        • Wolff R.A.
        • et al.
        Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience.
        Cancer. 2010; 116: 316-322
        • Bhatt A.
        • Rousset P.
        • Benzerdjeb N.
        • et al.
        Clinical and radiologic predictors of a pathologic complete response to neoadjuvant chemotherapy (NACT) in patients undergoing cytoreductive surgery for colorectal peritoneal metastases: results of a prospective multi-center study.
        Ann Surg Oncol. 2021; 28: 3840-3849
        • Des Guetz G.
        • Nicolas P.
        • Perret G.Y.
        • Morere J.F.
        • Uzzan B.
        Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis.
        Eur J Cancer. 2010; 46: 1049-1055
        • Biagi J.J.
        • Raphael M.J.
        • Mackillop W.J.
        • Kong W.
        • King W.D.
        • Booth C.M.
        Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis.
        JAMA. 2011; 305: 2335-2342
        • Argilés G.
        • Tabernero J.
        • Labianca R.
        • et al.
        Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2020; 31: 1291-1305
        • Loupakis F.
        • Sharma S.
        • Derouazi M.
        • et al.
        Detection of molecular residual disease using personalized circulating tumor DNA assay in patients with colorectal cancer undergoing resection of metastases.
        JCO Precis Oncol. 2021; 5
        • Baumgartner J.M.
        • Riviere P.
        • Lanman R.B.
        • et al.
        Prognostic utility of pre- and postoperative circulating tumor DNA liquid biopsies in patients with peritoneal metastases.
        Ann Surg Oncol. 2020; 27: 3259-3267
        • Kothary V.
        • Eng O.
        • Polite B.N.
        • et al.
        Correlation of circulating tumor DNA (ctDNA) with clinical outcomes in appendiceal cancers (AC).
        J Clin Oncol. 2022; 40 (29-29)